SOLID TUMOURS:@0.084848:0.038601:0.266058:0.038601:0.266058:0.019343:0.084848:0.019343:0.011712:0.020438:0.010866:0.005315:0.017498:0.006515:0.010019:0.015405:0.021613:0.020438:0.015405:0.014276:0.011712
52:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
the oestrogen  receptor  (ER) in previously :@0.084242:0.096166:0.480484:0.096166:0.480484:0.080410:0.084242:0.080410:0.005944:0.011157:0.011928:0.008038:0.012604:0.012508:0.007466:0.006523:0.005713:0.012604:0.012950:0.012508:0.011738:0.005330:0.003271:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.005330:0.003271:0.007100:0.010314:0.011680:0.007100:0.008621:0.003848:0.011738:0.008621:0.013123:0.005715:0.012508:0.010660:0.003848:0.012604:0.011699:0.007466:0.003848:0.010314:0.005330
treated patients.:@0.084242:0.112583:0.239869:0.112583:0.239869:0.096827:0.084242:0.096827:0.006523:0.005709:0.012508:0.013143:0.006523:0.012508:0.013181:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
CDK pathway  is  overactive in a num-:@0.102426:0.129000:0.475136:0.129000:0.475136:0.113244:0.102426:0.113244:0.015644:0.014316:0.011372:0.009794:0.013123:0.013143:0.006523:0.011738:0.015990:0.013143:0.010314:0.005330:0.004476:0.003848:0.007466:0.005330:0.004476:0.012604:0.010660:0.012508:0.005792:0.013143:0.012450:0.006523:0.003848:0.010660:0.012508:0.009794:0.003848:0.011738:0.009794:0.013143:0.009794:0.011738:0.011699:0.018049:0.006388
ber  of  cancers,  including breast cancer. :@0.084242:0.145418:0.480499:0.145418:0.480499:0.129662:0.084242:0.129662:0.013123:0.012508:0.005792:0.005330:0.003508:0.012604:0.006042:0.005330:0.003506:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466:0.005330:0.005330:0.003504:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.008852:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.008852:0.012450:0.013143:0.011738:0.012450:0.012508:0.004374:0.005330:0.005330
CDK inhibition leads to  activation of the :@0.084242:0.161835:0.480492:0.161835:0.480492:0.146079:0.084242:0.146079:0.015644:0.014316:0.011372:0.008928:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.003848:0.012604:0.011738:0.008928:0.003848:0.012508:0.013143:0.013181:0.007466:0.008928:0.006523:0.012604:0.005330:0.003589:0.013143:0.012450:0.006523:0.003848:0.010660:0.013143:0.006523:0.003848:0.012604:0.011738:0.008928:0.012604:0.006042:0.008928:0.006523:0.011738:0.012508:0.005330
tumour-suppressor gene,  Rb, leading to :@0.084242:0.178253:0.480497:0.178253:0.480497:0.162497:0.084242:0.162497:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.006388:0.007466:0.011699:0.013123:0.013123:0.005705:0.012508:0.007466:0.007466:0.012604:0.005792:0.011430:0.012950:0.012508:0.011738:0.012508:0.005330:0.005330:0.006086:0.011680:0.013123:0.005330:0.011430:0.003848:0.012508:0.013143:0.013181:0.003848:0.011738:0.012950:0.011430:0.006523:0.012604:0.005330
cell-cycle arrest.:@0.084242:0.194670:0.236663:0.194670:0.236663:0.178914:0.084242:0.178914:0.012450:0.012508:0.003848:0.003848:0.006388:0.012450:0.010314:0.012450:0.003848:0.012508:0.005330:0.013143:0.005792:0.005717:0.012508:0.007466:0.006523:0.005330
For patients in whom chemotherapy  is :@0.102426:0.211087:0.480472:0.211087:0.480472:0.195331:0.102426:0.195331:0.009333:0.012604:0.005792:0.008871:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.008871:0.003848:0.011738:0.008871:0.015990:0.011738:0.012604:0.018049:0.008871:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.003531:0.003848:0.007466:0.005330
deemed appropriate, single-agent chem-:@0.084242:0.227505:0.475158:0.227505:0.475158:0.211749:0.084242:0.211749:0.013181:0.012508:0.012508:0.018049:0.012508:0.013181:0.004753:0.013143:0.013123:0.013123:0.005721:0.012604:0.013123:0.005792:0.003848:0.013143:0.006523:0.012508:0.005330:0.004753:0.007466:0.003848:0.011738:0.012950:0.003848:0.012508:0.006388:0.013143:0.012950:0.012508:0.011738:0.006523:0.004753:0.012450:0.011738:0.012508:0.018049:0.006388
otherapy  is preferred over  combination :@0.084242:0.243922:0.480490:0.243922:0.480490:0.228166:0.084242:0.228166:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.006050:0.003848:0.007466:0.011392:0.013123:0.005717:0.012508:0.006042:0.012508:0.005792:0.005703:0.012508:0.013181:0.011392:0.012604:0.010660:0.012508:0.005792:0.005330:0.006052:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
chemotherapy  (in the  absence  of  a vis-:@0.084242:0.260340:0.475152:0.260340:0.475152:0.244584:0.084242:0.244584:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.003637:0.007100:0.003848:0.011738:0.008986:0.006523:0.011738:0.012508:0.005330:0.003645:0.013143:0.013123:0.007466:0.012508:0.011738:0.012450:0.012508:0.005330:0.003646:0.012604:0.006042:0.005330:0.003646:0.013143:0.008986:0.010660:0.003848:0.007478:0.006388
ceral crisis), as there is no prospective evi-:@0.084242:0.276757:0.475146:0.276757:0.475146:0.261001:0.084242:0.261001:0.012450:0.012508:0.005792:0.013143:0.003848:0.005811:0.012450:0.005792:0.003848:0.007466:0.003848:0.007466:0.007100:0.005330:0.005825:0.013143:0.007466:0.005811:0.006523:0.011738:0.012508:0.005705:0.012508:0.005811:0.003848:0.007466:0.005811:0.011738:0.012604:0.005802:0.013123:0.005715:0.012604:0.007466:0.013123:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.005811:0.012508:0.010660:0.003848:0.006388
dence to demonstrate the survival benefit :@0.084242:0.293174:0.480499:0.293174:0.480499:0.277418:0.084242:0.277418:0.013181:0.012508:0.011738:0.012450:0.012508:0.005142:0.006523:0.012604:0.005142:0.013181:0.012508:0.018049:0.012604:0.011738:0.007466:0.006523:0.005792:0.013143:0.006523:0.012508:0.005138:0.006523:0.011738:0.012508:0.005140:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005165:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.005330
of combination chemotherapy  over sin-:@0.084242:0.309592:0.475144:0.309592:0.475144:0.293836:0.084242:0.293836:0.012604:0.006042:0.010275:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.010275:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013123:0.013123:0.010314:0.005330:0.004957:0.012604:0.010660:0.012508:0.005792:0.010275:0.007466:0.003848:0.011738:0.006388
gle-agent sequential chemotherapy.:@0.084242:0.326009:0.429682:0.326009:0.429682:0.310253:0.084242:0.310253:0.012950:0.003848:0.012508:0.006388:0.013143:0.012950:0.012508:0.011738:0.006523:0.005330:0.007466:0.012508:0.013123:0.011699:0.012508:0.011738:0.006523:0.003848:0.013143:0.003848:0.005330:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
Chemotherapy  options to be consid-:@0.102426:0.342427:0.475160:0.342427:0.475160:0.326671:0.102426:0.326671:0.015644:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.006839:0.012604:0.013123:0.006523:0.003848:0.012604:0.011738:0.007466:0.012180:0.006523:0.012604:0.012180:0.013123:0.012508:0.012180:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.006388
ered for  this indication include anthra-:@0.084242:0.358844:0.475158:0.358844:0.475158:0.343088:0.084242:0.343088:0.012508:0.005711:0.012508:0.013181:0.012469:0.006042:0.012604:0.005792:0.005330:0.007129:0.006523:0.011738:0.003848:0.007466:0.012469:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.012469:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.012469:0.013143:0.011738:0.006523:0.011738:0.005792:0.013143:0.006388
cyclines, taxanes, capecitabine, vinorel-:@0.084242:0.375261:0.475150:0.375261:0.475150:0.359505:0.084242:0.359505:0.012450:0.010314:0.012450:0.003848:0.003848:0.011738:0.012508:0.007466:0.005330:0.010275:0.006523:0.013143:0.009236:0.013143:0.011738:0.012508:0.007466:0.005330:0.010275:0.012450:0.013143:0.013123:0.012508:0.012450:0.003848:0.006523:0.013143:0.013123:0.003848:0.011738:0.012508:0.005330:0.010275:0.010660:0.003848:0.011738:0.012604:0.005713:0.012508:0.003848:0.006388
bine, gemcitabine, eribulin and cisplatin, :@0.084242:0.391679:0.480482:0.391679:0.480482:0.375923:0.084242:0.375923:0.013123:0.003848:0.011738:0.012508:0.005330:0.008140:0.012950:0.012508:0.018049:0.012450:0.003848:0.006523:0.013143:0.013123:0.003848:0.011738:0.012508:0.005330:0.008140:0.012508:0.005792:0.003848:0.013123:0.011699:0.003848:0.003848:0.011738:0.008140:0.013143:0.011738:0.013181:0.008140:0.012450:0.003848:0.007466:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.005330:0.005330
among  others.  The  final  choice  of  drug :@0.084242:0.408096:0.480497:0.408096:0.480497:0.392340:0.084242:0.392340:0.013143:0.018049:0.012604:0.011738:0.012950:0.005330:0.005013:0.012604:0.006523:0.011738:0.012508:0.005792:0.007466:0.005330:0.005330:0.005007:0.008197:0.011738:0.012508:0.005330:0.005013:0.004686:0.004686:0.011738:0.013143:0.003848:0.005330:0.005020:0.012450:0.011738:0.012604:0.003848:0.012450:0.012508:0.005330:0.005022:0.012604:0.006042:0.005330:0.005016:0.013181:0.005792:0.011699:0.012950:0.005330
depends on toxicities, previous therapies, :@0.084242:0.424513:0.480492:0.424513:0.480492:0.408758:0.084242:0.408758:0.013181:0.012508:0.013123:0.012508:0.011738:0.013181:0.007466:0.007274:0.012604:0.011738:0.007264:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.003848:0.012508:0.007466:0.005330:0.007274:0.013123:0.005715:0.012508:0.010660:0.003848:0.012604:0.011699:0.007466:0.007274:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.003848:0.012508:0.007466:0.005330:0.005330
and patient preferences.:@0.084242:0.440931:0.317966:0.440931:0.317966:0.425175:0.084242:0.425175:0.013143:0.011738:0.013181:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.005330:0.013123:0.005709:0.012508:0.006042:0.012508:0.005707:0.012508:0.011738:0.012450:0.012508:0.007466:0.005330
MALE BREAST CANCER:@0.084242:0.474345:0.334950:0.474345:0.334950:0.454748:0.084242:0.454748:0.021167:0.017404:0.010348:0.012230:0.006585:0.013641:0.013641:0.012230:0.017404:0.012230:0.009878:0.006585:0.018344:0.017404:0.017404:0.018344:0.012230:0.013641
Male breast cancer is a rare disease, and :@0.084242:0.493053:0.480459:0.493053:0.480459:0.477297:0.084242:0.477297:0.017684:0.013143:0.003848:0.012508:0.006004:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.006004:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.006004:0.003848:0.007466:0.006004:0.013143:0.006004:0.005792:0.013143:0.005711:0.012508:0.006004:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.006004:0.013143:0.011738:0.013181:0.005330
accounts for 0.5-1% of all breast cancers :@0.084242:0.509470:0.480490:0.509470:0.480490:0.493714:0.084242:0.493714:0.013143:0.012450:0.012450:0.012604:0.011699:0.011738:0.006523:0.007466:0.007716:0.006042:0.012604:0.005792:0.007705:0.010660:0.005330:0.010660:0.006388:0.010660:0.014913:0.007716:0.012604:0.006042:0.007716:0.013143:0.003848:0.003848:0.007716:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.007716:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466:0.005330
diagnosed in the US.:@0.084242:0.525888:0.274723:0.525888:0.274723:0.510132:0.084242:0.510132:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.012508:0.013181:0.005330:0.003848:0.011738:0.005330:0.006523:0.011738:0.012508:0.005330:0.012604:0.009583:0.005330
The  treatment  recommendations  for :@0.102426:0.542305:0.480492:0.542305:0.480492:0.526549:0.102426:0.526549:0.008197:0.011738:0.012508:0.005330:0.011507:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.011505:0.005713:0.012508:0.012450:0.012604:0.018049:0.018049:0.012508:0.011738:0.013181:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.011505:0.006042:0.012604:0.005792:0.005330
male breast cancer are adapted from the :@0.084242:0.558723:0.480486:0.558723:0.480486:0.542967:0.084242:0.542967:0.018049:0.013143:0.003848:0.012508:0.004580:0.013123:0.005713:0.012508:0.013143:0.007466:0.006523:0.004580:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.004570:0.013143:0.005715:0.012508:0.004580:0.013143:0.013181:0.013143:0.013123:0.006523:0.012508:0.013181:0.004580:0.006042:0.005711:0.012604:0.018049:0.004580:0.006523:0.011738:0.012508:0.005330
guidelines for the management of female :@0.084242:0.575140:0.480492:0.575140:0.480492:0.559384:0.084242:0.559384:0.012950:0.011699:0.003848:0.013181:0.012508:0.003848:0.003848:0.011738:0.012508:0.007466:0.005407:0.006042:0.012604:0.005792:0.005407:0.006523:0.011738:0.012508:0.005407:0.018049:0.013143:0.011738:0.013143:0.012950:0.012508:0.018049:0.012508:0.011738:0.006523:0.005397:0.012604:0.006042:0.005407:0.006042:0.012508:0.018049:0.013143:0.003848:0.012508:0.005330
breast cancers, as there is a paucity of :@0.084242:0.591557:0.480472:0.591557:0.480472:0.575801:0.084242:0.575801:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.009679:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466:0.005330:0.009679:0.013143:0.007466:0.009679:0.006523:0.011738:0.012508:0.005705:0.012508:0.009679:0.003848:0.007466:0.009679:0.013143:0.009679:0.013123:0.013143:0.011699:0.012450:0.003848:0.006523:0.010314:0.009679:0.012604:0.006042:0.005330
clinical trials in this patient population.:@0.084242:0.607975:0.436840:0.607975:0.436840:0.592219:0.084242:0.592219:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.005330:0.006523:0.005792:0.003848:0.013143:0.003848:0.007466:0.005330:0.003848:0.011738:0.005330:0.006523:0.011738:0.003848:0.007466:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.005330:0.013123:0.012604:0.013123:0.011699:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
Male breast cancers are higher  in pa-:@0.102426:0.624392:0.475142:0.624392:0.475142:0.608636:0.102426:0.608636:0.017684:0.013143:0.003848:0.012508:0.008890:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.008890:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466:0.008890:0.013143:0.005715:0.012508:0.008890:0.011738:0.003848:0.012950:0.011738:0.012508:0.005792:0.005330:0.003550:0.003848:0.011738:0.008890:0.013123:0.013143:0.006388
tients who harbour a genetic mutation of :@0.084242:0.640809:0.480503:0.640809:0.480503:0.625054:0.084242:0.625054:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.006610:0.015990:0.011738:0.012604:0.006606:0.011738:0.013143:0.005792:0.013123:0.012604:0.011699:0.005792:0.006602:0.013143:0.006619:0.012950:0.012508:0.011738:0.012508:0.006523:0.003848:0.012450:0.006619:0.018049:0.011699:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.006604:0.012604:0.006042:0.005330
BRCA 2 more than BRCA 1. BRCA 2-posi-:@0.084242:0.657227:0.475148:0.657227:0.475148:0.641471:0.084242:0.641471:0.011045:0.011680:0.015644:0.014239:0.007705:0.010660:0.007716:0.018049:0.012604:0.005709:0.012508:0.007703:0.006523:0.011738:0.013143:0.011738:0.007703:0.011045:0.011680:0.015644:0.014239:0.007705:0.010660:0.005330:0.007707:0.011045:0.011680:0.015644:0.014239:0.007701:0.010660:0.006388:0.013123:0.012604:0.007466:0.003848:0.006388
tive men have a 6% absolute lifetime risk :@0.084242:0.673644:0.480501:0.673644:0.480501:0.657888:0.084242:0.657888:0.006523:0.003848:0.010660:0.012508:0.007639:0.018049:0.012508:0.011738:0.007639:0.011738:0.013143:0.010660:0.012508:0.007639:0.013143:0.007639:0.010660:0.014913:0.007639:0.013143:0.013123:0.007466:0.012604:0.003848:0.011699:0.006523:0.012508:0.007639:0.003848:0.003848:0.006042:0.012508:0.006523:0.003848:0.018049:0.012508:0.007639:0.005792:0.003848:0.007466:0.009660:0.005330
of developing breast cancer, significantly :@0.084242:0.690062:0.480476:0.690062:0.480476:0.674306:0.084242:0.674306:0.012604:0.006042:0.007045:0.013181:0.012508:0.010660:0.012508:0.003848:0.012604:0.013123:0.003848:0.011738:0.012950:0.007048:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.007050:0.012450:0.013143:0.011738:0.012450:0.012508:0.003764:0.005330:0.007048:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.003848:0.010314:0.005330
higher than the average man. Other non-:@0.084242:0.706479:0.475164:0.706441:0.475164:0.690685:0.084242:0.690723:0.011738:0.003848:0.012950:0.011738:0.012508:0.005792:0.006042:0.006523:0.011738:0.013143:0.011738:0.006042:0.006523:0.011738:0.012508:0.006042:0.013143:0.010660:0.012508:0.005792:0.013143:0.012950:0.012508:0.006042:0.018049:0.013143:0.011738:0.005330:0.003514:0.016722:0.006523:0.011738:0.012508:0.005792:0.006042:0.011738:0.012604:0.011738:-0.018863
 :@0.369846:0.700822:0.372954:0.700822:0.372954:0.691637:0.369846:0.691637:0.003107
BRCA mutations, such as PTEN, PALB2, P53, :@0.084235:0.722859:0.480475:0.722859:0.480475:0.707103:0.084235:0.707103:0.011045:0.011680:0.015644:0.014239:0.004965:0.018049:0.011699:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.004965:0.007466:0.011699:0.012450:0.011738:0.004965:0.013143:0.007466:0.004965:0.011392:0.008197:0.010314:0.014228:0.005330:0.004965:0.009960:0.014239:0.008890:0.011045:0.010660:0.005330:0.004965:0.011392:0.010660:0.010660:0.005330:0.005330
may also be implicated.:@0.084235:0.739276:0.310275:0.739276:0.310275:0.723520:0.084235:0.723520:0.018049:0.013143:0.010314:0.005330:0.013143:0.003848:0.007466:0.012604:0.005330:0.013123:0.012508:0.005330:0.003848:0.018049:0.013123:0.003848:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.005330
In addition, conditions that increase the :@0.102419:0.755693:0.480488:0.755693:0.480488:0.739937:0.102419:0.739937:0.004349:0.011738:0.005838:0.013143:0.013181:0.013181:0.003848:0.006523:0.003848:0.012604:0.011738:0.005330:0.005834:0.012450:0.012604:0.011738:0.013181:0.003848:0.006523:0.003848:0.012604:0.011738:0.007466:0.005840:0.006523:0.011738:0.013143:0.006523:0.005834:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.005840:0.006523:0.011738:0.012508:0.005330
oestrogen  ratio,  e.g.,  obesity,  gynaeco-:@0.084235:0.772111:0.475152:0.772111:0.475152:0.756355:0.084235:0.756355:0.012604:0.012508:0.007466:0.006523:0.005707:0.012604:0.012950:0.012508:0.011738:0.005330:0.005619:0.005792:0.013143:0.006523:0.003848:0.012604:0.005330:0.005330:0.005628:0.012508:0.005330:0.012950:0.005330:0.005330:0.005330:0.005617:0.012604:0.013123:0.012508:0.007466:0.003848:0.006523:0.010314:0.005330:0.005330:0.005626:0.012950:0.010314:0.011738:0.013143:0.012508:0.012450:0.012604:0.006388
mastia, alcohol, marijuana use, and Kline-:@0.084235:0.788528:0.475164:0.788528:0.475164:0.772772:0.084235:0.772772:0.018049:0.013143:0.007466:0.006523:0.003848:0.013143:0.005330:0.005734:0.013143:0.003848:0.012450:0.012604:0.011738:0.012604:0.003848:0.005330:0.005723:0.018049:0.013143:0.005792:0.003848:0.003906:0.011699:0.013143:0.011738:0.013143:0.005734:0.011699:0.007466:0.012508:0.005330:0.005719:0.013143:0.011738:0.013181:0.005723:0.011372:0.003848:0.003848:0.011738:0.012508:0.006388
felter syndrome may increase the risk of :@0.084235:0.804946:0.480488:0.804946:0.480488:0.789190:0.084235:0.789190:0.006042:0.012508:0.003848:0.006523:0.012508:0.005792:0.009179:0.007466:0.010314:0.011738:0.013181:0.005711:0.012604:0.018049:0.012508:0.009179:0.018049:0.013143:0.010314:0.009179:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.009179:0.006523:0.011738:0.012508:0.009179:0.005792:0.003848:0.007466:0.009660:0.009179:0.012604:0.006042:0.005330
male breast cancer.:@0.084235:0.821363:0.272912:0.821363:0.272912:0.805607:0.084235:0.805607:0.018049:0.013143:0.003848:0.012508:0.005330:0.013123:0.005717:0.012508:0.013143:0.007466:0.006523:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.004372:0.005330
Patients with non-metastatic  breast :@0.102419:0.837780:0.480484:0.837780:0.480484:0.822024:0.102419:0.822024:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.020128:0.015990:0.003848:0.006523:0.011738:0.020128:0.011738:0.012604:0.011738:0.006388:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330:0.014788:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.005330
cancer are managed with surgery,  ra-:@0.084235:0.854198:0.475150:0.854198:0.475150:0.838442:0.084235:0.838442:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.012296:0.013143:0.005713:0.012508:0.012296:0.018049:0.013143:0.011738:0.013143:0.012950:0.012508:0.013181:0.012296:0.015990:0.003848:0.006523:0.011738:0.012296:0.007466:0.011699:0.005809:0.012950:0.012508:0.005792:0.010314:0.005330:0.005330:0.006956:0.005792:0.013143:0.006388
diation therapy, and adjuvant  hormonal :@0.084235:0.870615:0.480488:0.870615:0.480488:0.854859:0.084235:0.854859:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.008871:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.008871:0.013143:0.011738:0.013181:0.008871:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330:0.003529:0.011738:0.012604:0.006317:0.018049:0.012604:0.011738:0.013143:0.003848:0.005330
blockade with tamoxifen, if indicated. The :@0.084235:0.887032:0.480482:0.887032:0.480482:0.871277:0.084235:0.871277:0.013123:0.003848:0.012604:0.012450:0.009660:0.013143:0.013181:0.012508:0.005042:0.015990:0.003848:0.006523:0.011738:0.005042:0.006523:0.013143:0.018049:0.012604:0.009236:0.003848:0.006042:0.012508:0.011738:0.005330:0.005030:0.003848:0.006042:0.005042:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.005330:0.005042:0.008197:0.011738:0.012508:0.005330
majority of male breast cancers are en-:@0.084235:0.903450:0.475125:0.903450:0.475125:0.887694:0.084235:0.887694:0.018049:0.013143:0.003906:0.012604:0.005792:0.003848:0.006523:0.010314:0.009082:0.012604:0.006042:0.009082:0.018049:0.013143:0.003848:0.012508:0.009082:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.009082:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466:0.009082:0.013143:0.005715:0.012508:0.009082:0.012508:0.011738:0.006388
docrine-responsive.  There  are  insufficient :@0.084235:0.919867:0.480480:0.919867:0.480480:0.904111:0.084235:0.904111:0.013181:0.012604:0.012450:0.005792:0.003848:0.011738:0.012508:0.006388:0.005705:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.003848:0.010660:0.012508:0.005330:0.005330:0.004739:0.008197:0.011738:0.012508:0.005703:0.012508:0.005330:0.004734:0.013143:0.005715:0.012508:0.005330:0.004736:0.003848:0.011738:0.007466:0.011699:0.006042:0.004686:0.004686:0.012450:0.003848:0.012508:0.011738:0.006523:0.005330
data for the use of aromatase inhibitors in :@0.084235:0.936285:0.480478:0.936285:0.480478:0.920529:0.084235:0.920529:0.013181:0.013143:0.006523:0.013143:0.005869:0.006042:0.012604:0.005792:0.005848:0.006523:0.011738:0.012508:0.005850:0.011699:0.007466:0.012508:0.005855:0.012604:0.006042:0.005854:0.013143:0.005715:0.012604:0.018049:0.013143:0.006523:0.013143:0.007466:0.012508:0.005855:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007466:0.005859:0.003848:0.011738:0.005330
male breast cancer, and those patients :@0.523635:0.096206:0.919877:0.096206:0.919877:0.080450:0.523635:0.080450:0.018049:0.013143:0.003848:0.012508:0.009948:0.013123:0.005713:0.012508:0.013143:0.007466:0.006523:0.009948:0.012450:0.013143:0.011738:0.012450:0.012508:0.003766:0.005330:0.009948:0.013143:0.011738:0.013181:0.009948:0.006523:0.011738:0.012594:0.007466:0.012508:0.009948:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
treated with aromatase inhibitors must ei-:@0.523635:0.112465:0.914522:0.112465:0.914522:0.096709:0.523635:0.096709:0.006523:0.005711:0.012508:0.013143:0.006523:0.012508:0.013181:0.006677:0.015990:0.003848:0.006523:0.011738:0.006677:0.013143:0.005715:0.012604:0.018049:0.013143:0.006523:0.013143:0.007466:0.012508:0.006677:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007466:0.006677:0.018049:0.011699:0.007466:0.006523:0.006677:0.012508:0.003848:0.006388
ther  have undergone  an orchidectomy, :@0.523635:0.128723:0.919890:0.128723:0.919890:0.112968:0.523635:0.112968:0.006523:0.011738:0.012508:0.005792:0.005330:0.004526:0.011738:0.013143:0.010660:0.012508:0.009871:0.011699:0.011738:0.013181:0.012508:0.005805:0.012950:0.012604:0.011738:0.012508:0.005330:0.004526:0.013143:0.011738:0.009871:0.012604:0.005651:0.012450:0.011738:0.003848:0.013181:0.012508:0.012450:0.006523:0.012604:0.018049:0.010314:0.005330:0.005330
or be treated with an LHRH agonist.:@0.523635:0.144982:0.853163:0.144982:0.853163:0.129226:0.523635:0.129226:0.012604:0.005792:0.005330:0.013123:0.012508:0.005330:0.006523:0.005698:0.012508:0.013143:0.006523:0.012508:0.013181:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.013143:0.011738:0.005330:0.008890:0.013143:0.011680:0.013143:0.005330:0.013143:0.012950:0.012604:0.011738:0.003848:0.007466:0.006523:0.005330
The approach to treatment of metastat-:@0.541819:0.161241:0.914552:0.161241:0.914552:0.145485:0.541819:0.145485:0.008197:0.011738:0.012508:0.004793:0.013143:0.013123:0.013123:0.005713:0.012604:0.013143:0.012450:0.011738:0.004797:0.006523:0.012604:0.004795:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.004793:0.012604:0.006042:0.004811:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.006388
ic breast cancer in males is similar to the :@0.523635:0.177499:0.919856:0.177499:0.919856:0.161743:0.523635:0.161743:0.003848:0.012450:0.007524:0.013123:0.005713:0.012508:0.013143:0.007466:0.006523:0.007524:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007524:0.003848:0.011738:0.007524:0.018049:0.013143:0.003848:0.012508:0.007466:0.007537:0.003848:0.007466:0.007535:0.007466:0.003848:0.018049:0.003848:0.003848:0.013143:0.005792:0.007539:0.006523:0.012604:0.007524:0.006523:0.011738:0.012508:0.005330
treatment in females.:@0.523635:0.193758:0.722001:0.193758:0.722001:0.178002:0.523635:0.178002:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.003848:0.011738:0.005330:0.006042:0.012508:0.018049:0.013143:0.003848:0.012508:0.007466:0.005330
Overall,  the prognosis of males  with :@0.541819:0.210017:0.919875:0.210017:0.919875:0.194261:0.541819:0.194261:0.016722:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.005330:0.005330:0.008844:0.006523:0.011738:0.012508:0.014162:0.013123:0.005711:0.012604:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.014162:0.012604:0.006042:0.014162:0.018049:0.013143:0.003848:0.012508:0.007466:0.005330:0.008844:0.015990:0.003848:0.006523:0.011738:0.005330
breast cancer is comparable to females.:@0.523635:0.226275:0.903961:0.226275:0.903961:0.210519:0.523635:0.210519:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.003848:0.007466:0.005330:0.012450:0.012604:0.018049:0.013123:0.013143:0.005792:0.013143:0.013123:0.003848:0.012508:0.005330:0.006523:0.012604:0.005330:0.006042:0.012508:0.018049:0.013143:0.003848:0.012508:0.007466:0.005330
WHEN TO REFER:@0.523636:0.259460:0.696262:0.259460:0.696262:0.239863:0.523636:0.239863:0.021167:0.015993:0.012230:0.017404:0.006585:0.009878:0.019756:0.006585:0.013641:0.012230:0.011289:0.012230:0.013641
Any  patient  who  presents with a breast :@0.523636:0.278018:0.919883:0.278018:0.919883:0.262262:0.523636:0.262262:0.014239:0.011738:0.010314:0.005330:0.004686:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.005330:0.004686:0.015990:0.011738:0.012604:0.005330:0.004684:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.006523:0.007466:0.010025:0.015990:0.003848:0.006523:0.011738:0.010025:0.013143:0.010025:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.005330
lump must  be  referred for  investigation :@0.523636:0.294276:0.919883:0.294276:0.919883:0.278520:0.523636:0.278520:0.003848:0.011699:0.018049:0.013123:0.011815:0.018049:0.011699:0.007466:0.006523:0.005330:0.006475:0.013123:0.012508:0.005330:0.006475:0.005713:0.012508:0.006042:0.012508:0.005792:0.005703:0.012508:0.013181:0.011815:0.006042:0.012604:0.005792:0.005330:0.006467:0.003848:0.011738:0.010660:0.012508:0.007466:0.006523:0.003848:0.012950:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
with a mammogram, and at least a breast :@0.523636:0.310535:0.919856:0.310535:0.919856:0.294779:0.523636:0.294779:0.015990:0.003848:0.006523:0.011738:0.004522:0.013143:0.004522:0.018049:0.013143:0.018049:0.018049:0.012604:0.012950:0.005792:0.013143:0.018049:0.005330:0.004522:0.013143:0.011738:0.013181:0.004522:0.013143:0.006523:0.004522:0.003848:0.012508:0.013143:0.007466:0.006523:0.004522:0.013143:0.004522:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.005330
ultrasound, regardless of age.:@0.523636:0.326793:0.799668:0.326793:0.799668:0.311038:0.523636:0.311038:0.011699:0.003848:0.006523:0.005792:0.013143:0.007466:0.012604:0.011699:0.011738:0.013181:0.005330:0.005330:0.005700:0.012508:0.012950:0.013143:0.005673:0.013181:0.003848:0.012508:0.007466:0.007466:0.005330:0.012604:0.006042:0.005330:0.013143:0.012950:0.012508:0.005330
A core biopsy, rather than a fine-needle :@0.541820:0.343052:0.919887:0.343052:0.919887:0.327296:0.541820:0.327296:0.014239:0.005222:0.012450:0.012604:0.005707:0.012508:0.005226:0.013123:0.003848:0.012604:0.013123:0.007466:0.010314:0.005330:0.005234:0.005792:0.013143:0.006523:0.011738:0.012508:0.005792:0.005215:0.006523:0.011738:0.013143:0.011738:0.005220:0.013143:0.005228:0.004686:0.004686:0.011738:0.012508:0.006388:0.011738:0.012508:0.012508:0.013181:0.003848:0.012508:0.005330
aspiration (FNA), must be performed on :@0.523636:0.359311:0.919904:0.359311:0.919904:0.343555:0.523636:0.343555:0.013143:0.007466:0.013123:0.003848:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.009525:0.007100:0.009333:0.014239:0.014230:0.007100:0.005330:0.009525:0.018049:0.011699:0.007466:0.006523:0.009525:0.013123:0.012508:0.009525:0.013123:0.012508:0.006710:0.006042:0.012604:0.006317:0.018049:0.012508:0.013181:0.009525:0.012604:0.011738:0.005330
the  breast mass, and  any axillary glands :@0.523636:0.375569:0.919887:0.375569:0.919887:0.359813:0.523636:0.359813:0.006523:0.011738:0.012508:0.005330:0.003235:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.008582:0.018049:0.013143:0.007466:0.007466:0.005330:0.008582:0.013143:0.011738:0.013181:0.005330:0.003242:0.013143:0.011738:0.010314:0.008582:0.013143:0.009236:0.003848:0.003848:0.003848:0.013143:0.005792:0.010314:0.008582:0.012950:0.003848:0.013143:0.011738:0.013181:0.007466:0.005330
must be cytologically evaluated.:@0.523636:0.391828:0.830283:0.391828:0.830283:0.376072:0.523636:0.376072:0.018049:0.011699:0.007466:0.006523:0.005330:0.013123:0.012508:0.005330:0.012450:0.010314:0.006523:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.003848:0.010314:0.005330:0.012508:0.010660:0.013143:0.003848:0.011699:0.013143:0.006523:0.012508:0.013181:0.005330
The histology must contain the following::@0.523636:0.424359:0.899979:0.424359:0.899979:0.408603:0.523636:0.408603:0.008197:0.011738:0.012508:0.005330:0.011738:0.003848:0.007466:0.006523:0.012604:0.003848:0.012604:0.012950:0.010314:0.005330:0.018049:0.011699:0.007466:0.006523:0.005330:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.005330:0.006523:0.011738:0.012508:0.005330:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330
n   :@0.523636:0.437546:0.546445:0.437546:0.546445:0.429105:0.523636:0.429105:0.009762:0.003566:0.005914:0.003566
The diagnosis:@0.542878:0.440665:0.666896:0.440665:0.666896:0.424909:0.542878:0.424909:0.008197:0.011738:0.012508:0.005330:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466
n   :@0.523636:0.453811:0.546445:0.453811:0.546445:0.445370:0.523636:0.445370:0.009762:0.003566:0.005914:0.003566
Grade of the tumour:@0.542878:0.456930:0.736053:0.456930:0.736053:0.441174:0.542878:0.441174:0.016779:0.005792:0.013143:0.013181:0.012508:0.005330:0.012604:0.006042:0.005330:0.006523:0.011738:0.012508:0.005330:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792
n   :@0.523636:0.470075:0.546445:0.470075:0.546445:0.461635:0.523636:0.461635:0.009762:0.003566:0.005914:0.003566
Subtype (lobular:@0.542878:0.473194:0.696240:0.473194:0.696240:0.457438:0.542878:0.457438:0.009583:0.011699:0.013123:0.006523:0.010314:0.013123:0.012508:0.005330:0.007100:0.003848:0.012604:0.013123:0.011699:0.003848:0.013143:0.005792
 vs :@0.696240:0.473194:0.725027:0.473194:0.725027:0.457438:0.696240:0.457438:0.005330:0.010660:0.007466:0.005330
ductal):@0.725027:0.473194:0.792972:0.473194:0.792972:0.457438:0.725027:0.457438:0.013181:0.011699:0.012450:0.006523:0.013143:0.003848:0.007100
n   :@0.523636:0.486340:0.546445:0.486340:0.546445:0.477900:0.523636:0.477900:0.009762:0.003566:0.005914:0.003566
The immnunohistochemistry, that :@0.542878:0.489459:0.853162:0.489459:0.853162:0.473703:0.542878:0.473703:0.008197:0.011738:0.012508:0.005330:0.003848:0.018049:0.018049:0.011738:0.011699:0.011738:0.012604:0.011738:0.003848:0.007466:0.006523:0.012604:0.012450:0.011738:0.012508:0.018049:0.003848:0.007466:0.006523:0.005792:0.010314:0.005330:0.005330:0.006523:0.011738:0.013143:0.006523:0.005330
includes oestrogen receptor, :@0.542878:0.505718:0.814720:0.505718:0.814720:0.489962:0.542878:0.489962:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.007466:0.005330:0.012604:0.012508:0.007466:0.006523:0.005711:0.012604:0.012950:0.012508:0.011738:0.005330:0.005698:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.003758:0.005330:0.005330
progesterone receptor expression, HER2 :@0.542878:0.521976:0.918677:0.521976:0.918677:0.506220:0.542878:0.506220:0.013123:0.005715:0.012604:0.012950:0.012508:0.007466:0.006523:0.012508:0.005703:0.012604:0.011738:0.012508:0.005330:0.005700:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.005330:0.012508:0.009236:0.013123:0.005698:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.005330:0.013143:0.010314:0.011680:0.010660:0.005330
neu expression and Ki 67:@0.542878:0.538235:0.770947:0.538235:0.770947:0.522479:0.542878:0.522479:0.011738:0.012508:0.011699:0.005330:0.012508:0.009236:0.013123:0.005703:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.013143:0.011738:0.013181:0.005330:0.011372:0.003848:0.005330:0.010660:0.010660
Once the diagnosis is made, the patient :@0.523636:0.570765:0.919887:0.570765:0.919887:0.555010:0.523636:0.555010:0.016722:0.011738:0.012450:0.012508:0.008128:0.006523:0.011738:0.012508:0.008130:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.008140:0.003848:0.007466:0.008140:0.018049:0.013143:0.013181:0.012508:0.005330:0.008130:0.006523:0.011738:0.012508:0.008124:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.005330
should be referred to a breast surgeon, :@0.523636:0.587024:0.919866:0.587024:0.919866:0.571268:0.523636:0.571268:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.009987:0.013123:0.012508:0.009987:0.005713:0.012508:0.006042:0.012508:0.005792:0.005709:0.012508:0.013181:0.009987:0.006523:0.012604:0.009987:0.013143:0.009987:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.009987:0.007466:0.011699:0.005809:0.012950:0.012508:0.012604:0.011738:0.005330:0.005330
preferably within a multidisciplinary team :@0.523636:0.603283:0.919893:0.603283:0.919893:0.587527:0.523636:0.587527:0.013123:0.005715:0.012508:0.006042:0.012508:0.005792:0.013143:0.013123:0.003848:0.010314:0.007793:0.015990:0.003848:0.006523:0.011738:0.003848:0.011738:0.007793:0.013143:0.007793:0.018049:0.011699:0.003848:0.006523:0.003848:0.013181:0.003848:0.007466:0.012450:0.003848:0.013141:0.003848:0.003848:0.011738:0.013143:0.005792:0.010314:0.007793:0.006523:0.012508:0.013143:0.018049:0.005330
for further management.:@0.523636:0.619541:0.754506:0.619541:0.754506:0.603785:0.523636:0.603785:0.006042:0.012604:0.005792:0.005330:0.006042:0.011699:0.005792:0.006523:0.011738:0.012508:0.005792:0.005330:0.018049:0.013143:0.011738:0.013143:0.012950:0.012508:0.018049:0.012508:0.011738:0.006523:0.005330
REFERENCES:@0.523636:0.649135:0.634472:0.649135:0.634472:0.633101:0.523636:0.633101:0.011161:0.010006:0.009236:0.010006:0.011161:0.010006:0.014239:0.015009:0.010006:0.010006
1. :@0.523636:0.665990:0.542588:0.665990:0.542588:0.651985:0.523636:0.651985:0.009476:0.004738:0.004738
 Couch FJ, Nathanson KL, Offit K. Two dec-:@0.559983:0.665990:0.914549:0.665990:0.914549:0.651985:0.559983:0.651985:0.000000:0.013906:0.011203:0.010399:0.011067:0.010434:0.005850:0.008296:0.008244:0.004738:0.005851:0.012657:0.011682:0.005798:0.010434:0.011682:0.010434:0.006636:0.011203:0.010434:0.005851:0.010109:0.007902:0.004738:0.005850:0.014864:0.005371:0.004165:0.004165:0.005798:0.005855:0.010109:0.004738:0.005851:0.007401:0.014214:0.011203:0.005855:0.011716:0.011118:0.011067:0.005679
ades after BRCA: setting paradigms in per-:@0.559983:0.680195:0.914539:0.680195:0.914539:0.666190:0.559983:0.666190:0.011682:0.011716:0.011118:0.006636:0.005183:0.011682:0.005371:0.005798:0.011118:0.005148:0.005183:0.009818:0.010382:0.013906:0.012657:0.004738:0.005183:0.006636:0.011118:0.005798:0.005798:0.003421:0.010434:0.011511:0.005183:0.011665:0.011682:0.005148:0.011682:0.011716:0.003421:0.011511:0.016044:0.006636:0.005183:0.003421:0.010434:0.005183:0.011665:0.011118:0.005148:0.005679
sonalized  cancer  care  and  prevention.  :@0.559983:0.694400:0.919277:0.694400:0.919277:0.680395:0.559983:0.680395:0.006636:0.011203:0.010434:0.011682:0.003421:0.003421:0.007269:0.011118:0.011716:0.004738:0.007738:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.007733:0.011067:0.011682:0.005080:0.011118:0.004738:0.007735:0.011682:0.010434:0.011716:0.004738:0.007738:0.011665:0.005080:0.011118:0.009476:0.011118:0.010434:0.005798:0.003421:0.011203:0.010434:0.004738:0.000000:0.004738
Science:@0.559983:0.708605:0.626724:0.708605:0.626724:0.694600:0.559983:0.694600:0.008518:0.011067:0.003421:0.011118:0.010434:0.011067:0.011118
. 2014;343(6178):1466.   .:@0.626724:0.708605:0.836252:0.708605:0.836252:0.694600:0.626724:0.694600:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738:0.004738:0.016865:0.004738
2. :@0.523636:0.722811:0.542588:0.722811:0.542588:0.708805:0.523636:0.708805:0.009476:0.004738:0.004738
  Houssami  N,  Turner R,  Morrow  M. Preop-:@0.559983:0.722811:0.914561:0.722811:0.914561:0.708805:0.559983:0.708805:0.004738:-0.004738:0.011682:0.011203:0.010399:0.006636:0.006636:0.011682:0.016044:0.003421:0.004738:0.004834:0.012657:0.004738:0.004738:0.004823:0.006498:0.010399:0.005502:0.010434:0.011118:0.005148:0.009561:0.010382:0.004738:0.004738:0.004823:0.015719:0.011203:0.005148:0.005070:0.011203:0.014214:0.004738:0.004823:0.015719:0.004738:0.009561:0.010126:0.005075:0.011118:0.011203:0.011665:0.005679
erative magnetic resonance imaging in :@0.559983:0.737016:0.919292:0.737016:0.919292:0.723011:0.559983:0.723011:0.011118:0.005148:0.011682:0.005798:0.003421:0.009476:0.011118:0.011272:0.016044:0.011682:0.011511:0.010434:0.011118:0.005798:0.003421:0.011067:0.011272:0.005078:0.011118:0.006636:0.011203:0.010434:0.011682:0.010434:0.011067:0.011118:0.011272:0.003421:0.016044:0.011682:0.011511:0.003421:0.010434:0.011511:0.011272:0.003421:0.010434:0.004738
breast cancer:  meta-analysis  of surgical :@0.559983:0.751221:0.919289:0.751221:0.919289:0.737216:0.559983:0.737216:0.011665:0.005080:0.011118:0.011682:0.006636:0.005798:0.011015:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004738:0.006264:0.016044:0.011118:0.005798:0.011682:0.005679:0.011682:0.010434:0.011682:0.003421:0.009168:0.006636:0.003421:0.006636:0.004738:0.006288:0.011203:0.005371:0.011015:0.006636:0.010399:0.005164:0.011511:0.003421:0.011067:0.011682:0.003421:0.004738
outcomes. :@0.559983:0.765426:0.652928:0.765426:0.652928:0.751421:0.559983:0.751421:0.011203:0.010399:0.005798:0.011067:0.011203:0.016044:0.011118:0.006636:0.004738:0.004738
Ann  Surg.:@0.655528:0.765426:0.736713:0.765426:0.736713:0.751421:0.655528:0.751421:0.012657:0.010434:0.010434:0.004738:0.002608:0.008518:0.010399:0.005148:0.011511:0.004738
  2013  Feb;257(2):249-:@0.736705:0.765426:0.914518:0.765426:0.914518:0.751421:0.736705:0.751421:0.004738:0.002617:0.009476:0.009476:0.009476:0.009476:0.004738:0.002631:0.008296:0.011118:0.011665:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679
55. Doi: 10.1097/SLA.0b013e31827a8d17.:@0.559983:0.779631:0.892748:0.779631:0.892748:0.765626:0.559983:0.765626:0.009476:0.009476:0.004738:0.004738:0.012726:0.011203:0.003421:0.004738:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.008518:0.007902:0.012657:0.004738:0.009476:0.011665:0.009476:0.009476:0.009476:0.011118:0.009476:0.009476:0.009476:0.009476:0.009476:0.011682:0.009476:0.011716:0.009476:0.009476:0.004738
3. :@0.523636:0.793837:0.542588:0.793837:0.542588:0.779831:0.523636:0.779831:0.009476:0.004738:0.004738
  Houssami  N, Turner R, :@0.559983:0.793837:0.748168:0.793837:0.748168:0.779831:0.559983:0.779831:0.004738:-0.004738:0.011682:0.011203:0.010399:0.006636:0.006636:0.011682:0.016044:0.003421:0.004738:0.003311:0.012657:0.004738:0.008039:0.006498:0.010399:0.005502:0.010434:0.011118:0.005148:0.008039:0.010382:0.004738:0.004738
et al:@0.751469:0.793837:0.791528:0.793837:0.791528:0.779831:0.751469:0.779831:0.011118:0.005798:0.008039:0.011682:0.003421
. An individual :@0.791528:0.793837:0.919280:0.793837:0.919280:0.779831:0.791528:0.779831:0.004738:0.008039:0.012657:0.010434:0.008039:0.003421:0.010434:0.011716:0.003421:0.009476:0.003421:0.011716:0.010399:0.011682:0.003421:0.004738
person data meta-analysis of preoperative :@0.559983:0.808042:0.919291:0.808042:0.919291:0.794036:0.559983:0.794036:0.011665:0.011118:0.005148:0.006636:0.011203:0.010434:0.004745:0.011716:0.011682:0.005798:0.011682:0.004755:0.016044:0.011118:0.005798:0.011682:0.005679:0.011682:0.010434:0.011682:0.003421:0.009168:0.006636:0.003421:0.006636:0.004770:0.011203:0.005371:0.004746:0.011665:0.005080:0.011118:0.011203:0.011665:0.011118:0.005148:0.011682:0.005798:0.003421:0.009476:0.011118:0.004738
magnetic  resonance  imaging  and breast :@0.559983:0.822247:0.919291:0.822247:0.919291:0.808242:0.559983:0.808242:0.016044:0.011682:0.011511:0.010434:0.011118:0.005798:0.003421:0.011067:0.004738:0.002980:0.005078:0.011118:0.006636:0.011203:0.010434:0.011682:0.010434:0.011067:0.011118:0.004738:0.002980:0.003421:0.016044:0.011682:0.011511:0.003421:0.010434:0.011511:0.004738:0.002985:0.011682:0.010434:0.011716:0.007731:0.011665:0.005080:0.011118:0.011682:0.006636:0.005798:0.004738
cancer  recurrence. :@0.559983:0.836452:0.734510:0.836452:0.734510:0.822447:0.559983:0.822447:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.008183:0.005078:0.011118:0.011067:0.010399:0.005148:0.005070:0.011118:0.010434:0.011067:0.011118:0.004738:0.004738
J Clin Oncol:@0.742691:0.836452:0.858967:0.836452:0.858967:0.822447:0.742691:0.822447:0.008244:0.012931:0.013906:0.003421:0.003421:0.010434:0.012931:0.014864:0.010434:0.011067:0.011203:0.003421
. 2014 :@0.858967:0.836452:0.919277:0.836452:0.919277:0.822447:0.858967:0.822447:0.004738:0.012931:0.009476:0.009476:0.009476:0.009476:0.004738
Feb;32(5):392-401.:@0.559983:0.850657:0.708859:0.850657:0.708859:0.836652:0.559983:0.836652:0.008296:0.011118:0.011665:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
4. :@0.523636:0.864862:0.542588:0.864862:0.542588:0.850857:0.523636:0.850857:0.009476:0.004738:0.004738
  Fayanju OM, Stoll CR, :@0.559983:0.864862:0.749345:0.864862:0.749345:0.850857:0.559983:0.850857:0.004738:-0.004738:0.008296:0.011682:0.009168:0.011682:0.010434:0.003472:0.010399:0.007594:0.014864:0.015719:0.004738:0.007594:0.008518:0.005798:0.011203:0.003421:0.003421:0.007594:0.013906:0.010382:0.004738:0.004738
et  al:@0.752184:0.864862:0.791788:0.864862:0.791788:0.850857:0.752184:0.850857:0.011118:0.005798:0.004738:0.002846:0.011682:0.003421
.  Contralateral :@0.791788:0.864862:0.919292:0.864862:0.919292:0.850857:0.791788:0.850857:0.004738:0.004738:0.002848:0.013906:0.011203:0.010434:0.005798:0.005148:0.011682:0.003421:0.011682:0.005798:0.011118:0.005148:0.011682:0.003421:0.004738
prophylactic mastectomy after unilateral :@0.559983:0.879068:0.919277:0.879068:0.919277:0.865062:0.559983:0.865062:0.011665:0.005080:0.011203:0.011665:0.010434:0.009168:0.003421:0.011682:0.011067:0.005798:0.003421:0.011067:0.009561:0.016044:0.011682:0.006636:0.005798:0.011118:0.011067:0.005798:0.011203:0.016044:0.009168:0.009561:0.011682:0.005371:0.005798:0.011118:0.005148:0.009561:0.010399:0.010434:0.003421:0.003421:0.011682:0.005798:0.011118:0.005148:0.011682:0.003421:0.004738
breast cancer:  a systematic review and :@0.559983:0.893273:0.919280:0.893273:0.919280:0.879268:0.559983:0.879268:0.011665:0.005080:0.011118:0.011682:0.006636:0.005798:0.010006:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004738:0.005256:0.011682:0.010006:0.006636:0.009168:0.006636:0.005798:0.011118:0.016044:0.011682:0.005798:0.003421:0.011067:0.010006:0.005078:0.011118:0.009476:0.003421:0.011118:0.014214:0.010006:0.011682:0.010434:0.011716:0.004738
meta-analysis. :@0.559983:0.907478:0.682860:0.907478:0.682860:0.893473:0.559983:0.893473:0.016044:0.011118:0.005798:0.011682:0.005679:0.011682:0.010434:0.011682:0.003421:0.009168:0.006636:0.003421:0.006636:0.004738:0.004738
Ann Surg.:@0.682877:0.907478:0.761455:0.907478:0.761455:0.893473:0.682877:0.893473:0.012657:0.010434:0.010434:0.004738:0.008518:0.010399:0.005148:0.011511:0.004738
 2014;260(6):1000.:@0.761438:0.907478:0.906722:0.907478:0.906722:0.893473:0.761438:0.893473:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
5. :@0.523653:0.921683:0.542605:0.921683:0.542605:0.907678:0.523653:0.907678:0.009476:0.004738:0.004738
  Early Breast Cancer Trialists’  Collaborative :@0.560000:0.921683:0.919294:0.921683:0.919294:0.907678:0.560000:0.907678:0.004738:-0.004738:0.009168:0.011682:0.005148:0.003421:0.009168:0.007594:0.009818:0.005082:0.011118:0.011682:0.006636:0.005798:0.007594:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.007594:0.006773:0.005148:0.003421:0.011682:0.003421:0.003421:0.006636:0.005798:0.006636:0.006004:0.004738:0.002872:0.013906:0.011203:0.003421:0.003421:0.011682:0.011665:0.011203:0.005148:0.011682:0.005798:0.003421:0.009476:0.011118:0.004738
Group (EBCTCG). Long-term outcomes for :@0.560000:0.935888:0.919306:0.935888:0.919306:0.921883:0.560000:0.921883:0.014915:0.005078:0.011203:0.010399:0.011665:0.006115:0.006312:0.009168:0.009818:0.013906:0.007286:0.013906:0.014915:0.006312:0.004738:0.006113:0.007902:0.011203:0.010434:0.011511:0.005679:0.005798:0.011118:0.005609:0.016044:0.006123:0.011203:0.010399:0.005798:0.011058:0.011203:0.016044:0.011118:0.006636:0.006115:0.005371:0.011203:0.005148:0.004738